Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation ; volume:102 ; number:7 ; day:20 ; month:4 ; year:2023 ; pages:1915-1925 ; date:7.2023
Annals of hematology ; 102, Heft 7 (20.4.2023), 1915-1925, 7.2023

Creator
Martino, Massimo
Gori, Mercedes
Porto, Gaetana
Pellicano, Maria
Santoro, Ludovica
Verduci, Chiara
Canale, Filippo Antonio
Loteta, Barbara
Moscato, Tiziana
Alati, Caterina
Ieracitano, Maria Consuelo
Cuzzocrea, Amelia
Altomonte, Maria
Florenzano, Maria Teresa
Morabito, Antonella
Irrera, Giuseppe
Naso, Virginia
Pugliese, Marta
Console, Giuseppe
Ferreri, Anna
Imbalzano, Lucrezia
Tripepi, Giovanni
Pitino, Annalisa
Contributor
SpringerLink (Online service)

DOI
10.1007/s00277-023-05228-z
URN
urn:nbn:de:101:1-2023092508130547255411
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Martino, Massimo
  • Gori, Mercedes
  • Porto, Gaetana
  • Pellicano, Maria
  • Santoro, Ludovica
  • Verduci, Chiara
  • Canale, Filippo Antonio
  • Loteta, Barbara
  • Moscato, Tiziana
  • Alati, Caterina
  • Ieracitano, Maria Consuelo
  • Cuzzocrea, Amelia
  • Altomonte, Maria
  • Florenzano, Maria Teresa
  • Morabito, Antonella
  • Irrera, Giuseppe
  • Naso, Virginia
  • Pugliese, Marta
  • Console, Giuseppe
  • Ferreri, Anna
  • Imbalzano, Lucrezia
  • Tripepi, Giovanni
  • Pitino, Annalisa
  • SpringerLink (Online service)

Other Objects (12)

Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation

Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation

Altered t-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive t-cell therapy

Altered t-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive t-cell therapy

Altered T-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive T-cell therapy

Altered T-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive T-cell therapy

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation

Evaluation of gastrointestinal complications in Egyptian patients after autologous stem cell transplantation using melphalan-based regimens

Evaluation of gastrointestinal complications in Egyptian patients after autologous stem cell transplantation using melphalan-based regimens

Current status of autologous stem cell transplantation for multiple myeloma

Current status of autologous stem cell transplantation for multiple myeloma

Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation

Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest

Related objects